Skip to main content
PMC home page
Molecules logoLink to Molecules
. 2015 Jun 30;20(7):11994–12015. doi: 10.3390/molecules200711994

Synthesis and Biological Evaluation of Lipophilic 1,4-Naphthoquinone Derivatives against Human Cancer Cell Lines

Shao-Hung Wang 1, Chih-Yu Lo 2, Zhong-Heng Gwo 1, Hong-Jhih Lin 1, Lih-Geeng Chen 1, Cheng-Deng Kuo 3, Jin-Yi Wu 1,*
Editors: Jean Jacques Vanden Eynde, Annie Mayence, Tien L Huang
PMCID: PMC6331847  PMID: 26133763

Abstract

To examine the effect of hydrophobicity on the anticancer activity of 1,4-naphthoquinone derivatives, a series of compounds bearing a 2-O-alkyl-, 3-C-alkyl- or 2/3-N-morpholinoalkyl group were synthesized and evaluated for their anticancer activity against five human cancer cell lines in vitro. The cytotoxicity of these derivatives was assayed against HT-29, SW480, HepG2, MCF-7 and HL-60 cells by the MTT assay. Among them, 2-hydroxy-3-farnesyl-1,4-naphthoquinone (11a) was found to be the most cytotoxic against these cell lines. Our results showed that the effectiveness of compound 11a may be attributed to its suppression of the survival of HT-29. Secondly, in the Hoechst 33258 staining test, compound 11a-treated cells exhibited nuclear condensation typical of apoptosis. Additionally, cell cycle analysis by flow cytometry indicated that compound 11a arrested HT-29 cells in the S phase. Furthermore, cell death detected by Annexin V-FITC/propidium iodide staining showed that compound 11a efficiently induced apoptosis of HT-29 in a concentration-dependent manner. Taken together, compound 11a effectively inhibits colon cancer cell proliferation and may be a potent anticancer agent.

Keywords: 1,4-naphthoquinone; terpenoids; anticancer activity; human colon cancer cells HT-29; cell cycle distribution; apoptosis

1. Introduction

Millions of lives are lost because of cancer in the world each year and the number is increasing. However, greater than 30% of cancers are preventable [1] and some forms of cancer are curable regardless of when they are diagnosed, while many others are only curable if discovered at an early stage. Thus cancer remains a life-threatening disease and represents a serious peril to human health [2]. Chemotherapy is vital to cancer treatment and the majority of clinical antitumor agents have originated from natural products. Plants produce a wide range of secondary metabolites such as flavonoids, terpenoids, alkaloids, quinones, polyacetylene, and sugar as part of their defense mechanism against insects [3] and microbials [4]. Among these, 1,4-naphthoquinones, in particular, plumbagin (1), lawsone (2), juglone (3), and shikonin (4) [5] (Figure 1), are an important group of natural products, which have been employed in the development of potent phytochemicals because of their high abundance and relatively non-toxic nature. The 1,4-naphthoquinone pharmacophore is known to impart anticancer activity in a number of drugs, such as streptonigrin [6], mitomycins [7], and doxorubicin [8] among others. The anticancer activity of the 1,4-naphthoquinone skeleton has been the focus of recent research in the field [9,10].

Figure 1.

Figure 1

Open in a new tab

Chemical structures of plumbagin (1); lawsone (2); juglone (3) and shikonin (4).

Among 1,4-naphthoquinones, there are numerous interesting biologically active compounds such as atovaquone, plumbagin, lapachol, and menadione [11]. Nevertheless, a literature precedence revealed that plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), a wide type quinonoid, found in the plants of the Plumbaginaceae, Droseraceae, Ancestrocladceae, and Dioncophyllaceae families, possesses significant antimicrobial [12], antimalarial [13], antifilarial [14], antiprotozoal [15], anti-inflammatory [16], and anticancer properties [17,18,19].

Further, it was reported that monoterpenyl- and diterpenylnaphthoquinones derivatives had IC50 values in the micromolar range against several tumor cell lines [20]. These derivatives were synthesized through Diels-Alder addition of natural terpenoids and p-benzoquinones, followed by side chain transformation [21]. Additionally, several 1,4-naphthoquinone derivatives incorporating with hydroxyl groups at C-5 can provide enhanced anti-proliferative activity in in vivo and in vitro [22].

It was also reported that 1,4-naphthoquinones interfere with the electron transport and oxidative phosphorylation processes and play roles in enzyme inhibition, and DNA cross linking as well as have antifungal, antibacterial, and anticancer activities [7]. Nonetheless, many reported amino-1,4-naphthoquinones did not contain substituents on the benzene ring, although some studies [21,22] have shown that derivatives with side chains (alkyl or alkenyl) on the benzene ring considerably improved the cytotoxicity of the 1,4-naphthoquinone moiety.

In this study, we synthesized and evaluated the effect of incorporation of new alkyl or terpenyl moieties in 1,4-naphthoquinones, including lawsone substituted at the 2-C/3-O-position with alkyl or terpenyl groups and juglone substituted at position 2/3-N-morpholinoalkyl groups, with the aim to analyze the influence of these substituents on the cytotoxicity of these derivatives against human cancer cell lines. We prepared and evaluated C-2 amino substituted 1,4-naphthoquinones, a core structure present in numerous naturally occurring bioactive quinones, such as mitomycin C, as well as some synthetic compounds [23].

2. Results and Discussion

2.1. Chemistry

In general, 1,4-naphthoquionone derivatives were synthesized from lawsone (2) with alkyl, terpenyl, alkylamino, or morpholinealkylamino moieties through 2-O- or 3-C-alkylation. As shown in Scheme 1, synthesis of 5a,b–11a,b were carried out by reacting lawsone with selected alkyl or terpenyl bromide in dimethylformamide (DMF) using triethylamine as the base and sodium iodide (NaI) as the catalyst under N2 for 1 h according to the reported procedure [24]. The addition of an alkyl or terpenyl group to lawsone (2) gave two products at the 2-O-postion and 3-C-position in 40.0%–72.3% yield. The 3-C-substituted compounds were the major products while the 2-O-substituted compounds were obtained with a yield of less than 10%.

Scheme 1.

Synthesis of compounds 5a,b‒11a,b.

Scheme 1

Reagents and conditions: (a) NaI, triethylamine, DMF, N2, 1 h; (b) alkyl or terpenyl bromide, 40 °C, 3–7 days.

Open in a new tab

The synthesis of juglone (3) was via oxidation of commercially available 1,5-dihydroxy-naphthalene (12) in air, and dark, in the presence of periodic acid with a yield of 67.6%. Chemical transformation of juglone (3) to compounds 13a,b‒19a,b was then carried out according to the reported methods with some modifications [25]. Aminated juglone (3) was prepared by stirring it with a long chain amine in ethanol for 1 h under reflux to give 2-alkylaminojuglone and 3-alkylaminojuglone as major and minor products, respectively. Lastly, once the alkylamino substituted 1,4-naphthoquinone derivatives were obtained, other alkyl- or morpholinealkylamino-juglones were prepared by adding primary alkyl amines and morpholinealkyl amines to juglone (3) in ethanolic solution at room temperature. The two-step reaction and end products are illustrated in Scheme 2.

Scheme 2.

Synthesis of compounds 13a,b‒19a,b.

Scheme 2

Reagents and conditions: (a) HIO4, THF/H2O, rt, 30 min; (b) alkyl amine, EtOH, reflux, 1–5 h.

Open in a new tab

2.2. In Vitro Anti-Proliferative Activity by MTT Assay

The cytotoxic effects of the 31 1,4-naphthoquinone derivatives were tested in vitro against five human cancer cell lines: HT29 (colorectal adenocarcinoma), SW480 (colorectal adenocarcinoma), HepG2 (hepatocellular carcinoma), HL60 (leukemia), MCF-7 (breast adenocarcinoma) and normal murine embryonic liver BNL CL.2 cells, using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay [26]. 5-Fluorouracil (5-Fu), cisplatin and doxorubicin were used as positive controls. The concentration (in μM) of the test compounds which induced 50% inhibition of cell growth (IC50) is shown in Table 1.

Table 1.

IC50 values of plumbagin (1), lawsone (2) and its derivatives 5a,b–11a,b, 13a,b‒19a,b on the growth of human cancer cell lines for 48 h.

Compound cLogP a IC50 (μM) b (Mean ± SD)
HT-29 Colon SW480 Colon HepG2 Liver HL60 Leukemia MCF-7 Breast
Plumbagin (1) 2.78 3.67 ± 0.46 2.19 ± 0.65 2.32 ± 0.18 5.90 ± 1.21 20.89 ± 0.70
Lawsone (2) 1.68 >100 >100 >100 45.12 ± 7.90 >100
Juglone (3) 2.26 >50 >50 >50 46.95 ± 0.58 >50
5a 2.19 >100 97.09 ± 2.36 94.08 ± 2.63 >100 >100
5b 1.78 8.16 ± 1.16 4.23 ± 0.50 3.32 ± 0.66 16.40 ± 2.84 >25
6a 3.79 >100 >100 >100 >100 >100
6b 3.22 14.81 ± 0.65 2.02 ± 0.20 3.67 ± 0.84 20.04 ± 0.79 31.03 ± 0.32
7a 5.90 33.44 ± 1.48 9.73 ± 0.04 20.20 ± 3.52 >100 >50
7b 5.34 28.01 ± 3.52 8.51 ± 0.53 9.66 ± 0.50 23.42 ± 1.24 20.81 ± 3.67
8a 7.46 >25 >25 >25 >25 >25
8b 8.02 >25 >25 >25 >25 >25
9a 3.70 >100 >100 74.18 ± 2.61 >100 >100
9b 3.34 >50 20.72 ± 1.19 35.56 ± 1.13 >50 >50
10a 5.73 12.90 ± 2.13 14.14 ± 0.96 19.10 ± 0.26 9.12 ± 0.69 >100
10b 5.37 42.90 ± 1.13 44.23 ± 1.06 29.10 ± 1.21 29.56 ± 0.88 >100
11a 6.82 1.99 ± 0.04 2.02 ± 0.31 14.01 ± 2.70 5.41 ± 0.88 47.01 ± 0.47
11b 7.40 40.37 ± 0.75 37.16 ± 2.21 32.33 ± 1.46 35.10 ± 1.52 >100
13a 3.65 9.82 ± 1.51 16.17 ± 0.72 9.39 ± 0.12 45.69 ± 2.48 >100
13b 3.65 18.11 ± 1.68 8.28 ± 0.12 17.89 ± 0.14 6.50 ± 0.32 23.71 ± 0.82
14a 4.99 >50 >50 >50 >50 >50
14b 4.99 34.53 ± 1.20 15.13 ± 0.49 17.82 ± 2.29 >50 >50
15a 6.05 >50 >50 >50 >50 >50
15b 6.05 >50 20.23 ± 2.18 47.06 ± 0.63 >50 >50
16a 7.11 >50 >50 >50 >50 >50
16b 7.11 >50 >50 >50 >50 >50
17a 8.17 >20 >20 >20 >20 >20
17b 8.17 >20 >20 >20 >20 >20
18a 2.51 9.42 ± 0.45 8.86 ± 0.50 11.72 ± 0.42 8.42 ± 0.86 >50
18b 2.51 8.59 ± 0.67 5.19 ± 0.44 8.84 ± 0.07 6.49 ± 0.84 >50
19a 2.80 9.44 ± 0.32 4.66 ± 0.25 10.08 ± 0.57 6.35 ± 0.24 >50
19b 2.80 11.38 ± 1.51 3.86 ± 0.61 7.90 ± 0.16 7.76 ± 0.54 >50
Cisplatin - 24.07 ± 0.03 40.72 ± 1.18 36.07 ± 3.11 >100 >100
5-Fu - >100 32.72 ± 8.32 40.18 ± 7.63 >100 >100
Doxorubicin - 1.70 ± 0.20 0.53 ± 0.07 0.30 ± 0.02 14.26 ± 0.89 0.39 ± 0.06
Open in a new tab

a Calculated log value of partition coefficient by ChemDraw Ultra 8.0; b IC50 = compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the mean ± SD from the dose response curves of at least three independent experiments.

Of the 31 compounds tested, eleven compounds were bioactive and nine (5b, 6b, 7b, 10a, 11a, 18a, 18b, 19a and 19b) showed significant cell growth inhibition in four human cancer cells except MCF-7 cells. In addition, the anticancer activity of these compounds increased with the higher chain length of the terpenyl substituents, but not in long chain alkyl groups. This result suggests that the lipophilicity of terpenyl moiety of the 1,4-naphthoquinone derivatives at the 3-C-substituent affected the bioactivity of the compound (11a). In particular, among the bioactive ones, compound 11a exhibited the highest activity against the human colorectal HT-29 cell lines with an IC50 value of 1.99 ± 0.04 μM for 48 h. Compared to plumbagin (1)’s IC50 value of 3.67 ± 0.46 μM, derivative 11a was slightly more cytotoxic against human colorectal carcinoma HT-29 cells. No significant cell death was detected in normal murine embryonic liver BNL CL.2 cells treated with plumbagin (1) and 11a. Furthermore, in BNL CL.2 cells, only a marked effect on cell death (under 20%) was observed at the maximum concentration (20 μM) of these two compounds after 48 h treatment (see also Figure S1). It thus appeared that both plumbagin (1) and compound 11a are cytotoxic to human colorectal cancer cells with no significant adverse side effects toward normal cells. Namely, the lipophilic characteristics of the substituent at the 3-C-position of the farnesyl moieties of 1,4-naphthoquinone derivative 11a can remarkably enhance their anticancer activity against human cancer HT-29 cell lines. In other words, a higher anticancer activity because the longer terpenyl moiety of the 1,4-naphthoquinone derivative 11a enhanced their cell membrane permeability and bioavailability, thus increasing their cytotoxic activities.

2.3. Cytotoxic Activity of Plumbagin (1) and Compound 11a was Exhibited in a Time-Dependent Manner

In light of the cytotoxicity findings described above, we extended our study on the anti-proliferation efficacy of plumbagin (1) and lawsone derivative 11a against HT-29 cells to 24 h, 48 h and 72 h periods. The data on plumbagin (1) was used here as base case. As shown in Table 2, first of all, the cytotoxicity of compound 11a demonstrated, once again stronger bioactivity than that of plumbagin (1) in vitro. In addition, the growth inhibition of HT-29 cells induced by these two samples was in a time-dependent manner. The IC50 values of plumbagin (1) and 11a in HT-29 cells for 24 h, 48 h and 72 h incubation times were 4.72, 3.67, 2.10 μM and >20, 1.99, 0.84 μM, respectively. The results revealed that plumbagin (1) and 11a inhibited the cell viability of HT-29 cells in a time-dependent manner at longer time.

Table 2.

Cytotoxicity of plumbagin (1) and 11a on HT-29 for 24 h, 48 h, and 72 h.

Compound IC50 (μM) a (Mean ± SD)
24 h 48 h 72 h
Plumbagin (1) 4.72 ± 0.07 3.67 ± 0.46 2.10 ± 0.23
11a >20 1.99 ± 0.04 0.84 ± 0.12
Open in a new tab

a IC50 = compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the mean ± SD from the dose response curves of at least three independent experiments.

2.4. Nuclear Morphological Changes of HT-29 Cells Treated with Plumbagin (1) and Compound 11a

Apoptosis, shown by morphological changes, were detected through Hoechst 33258 staining in the HT-29 cells. The classical characteristics of apoptotic cells are chromatin condensation and nuclear fragmentation [27]. To further investigate the role apoptosis plays in the superior cytotoxicity of plumbagin (1) and the potent compound 11a, we incubated HT-29 cells, with plumbagin (1) and 11a, separately, for 48 h. The cells were then stained with Hoechst 33258, and examined by fluorescence microscopy for topical morphological changes. As shown in Figure 2, while the nuclei of the cells were round in shape and stained homogenously in the control without testing compound, those treated with plumbagin (1) and 11a showed typical morphological features of apoptotic cells based on cell shrinkage, chromatin condensation and nuclear fragmentation [28]. Evidently, the proliferation of the cancer cell is inhibited by the testing compounds in vitro.

Figure 2.

Figure 2

Figure 2

Open in a new tab

The morphological changes of HT-29 cells treated with 0–2.5 μM plumbagin (1) (A) and 11a (B) for 48 h. (magnification, 200×). (A,B) The upper panels showed the cell morphology under phase-contrast microscopy, and the lower panels display the Hoechst 33258-stained nuclear patterns take by fluorescence microscopy (magnification, 200×).

2.5. Cell Cycle Distribution Analysis Using Flow Cytometry

To probe the apoptotic effects of plumbagin (1) and 11a on cell cycle progression, HT-29 cells were treated once again with these compounds, separately, at different concentrations for 48 h. The cell cycle distribution of the cancer cells was analyzed by flow cytometry, and the sub-G1 phase analyzed by flow cytometry with propidium iodide (PI) staining [28]. The control of the experiment was the untreated cells. As illustrated in Figure 3, only a small fraction of apoptotic cells (0.8%) was detected in the control as well as in plumbagin (1) at a low concentration of 2.5 μM. However, as plumbagin (1) dosage increased from 0.5 to 2.5 μM, the fraction of apoptotic cell went up substantially from 4.5% to 7.6% in a concentration-dependent manner. As for compound 11a, the apoptotic effect meagerly laid between 10.7% to 27.8% across the treatment range of 0.5–2.5 μM and induced cell accumulation in the S phase.

Figure 3.

Figure 3

Figure 3

Open in a new tab

(A) The effects of the 48 h treatments with 0–2.5 μM plumbagin (1) and 11a on cell cycle distribution of HT-29. After treatment, cells were fixed and stained with PI, and the cell cycle distribution was examined by flow cytometry; (B) Quantitative data of cell cycle analysis of HT-29 treated with 0‒2.5 μM plumbagin (1) and 11a for 48 h; (C) Compared with control, the treated with plumbagin (1) and 11a shows the obvious increase in sub-G1 fraction. Each value represents the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01 vs. control.

2.6. Apoptotic Analyses-Annexin V-FITC/PI Double Staining and Flow Cytometry Analyses

Quantitative analysis of apoptotic effects of plumbagin (1) and 11a on HT-29 cells was conducted by flow cytometry using Annexin V-FITC and PI double staining. This was to study in depth the bioactivities of plumbagin (1) and 11a against HT-29 cells. Thus, the cancer cells were treated with vehicle alone as control or with one of the two testing compounds at different concentrations (0.5–2.5 μM). After 48 h, the samples were double-stained with Annexin V-FITC and PI [29]. The percentages of cell populations at various stages of apoptosis were exhibited in Figure 4. The total apoptosis rates were 1.08%, 8.65%, 13.21%, and 21.02% at concentrations of 0, 0.5, 1.0, and 2.5 μM of compound 11a, respectively. Though the data pointed out that the distributions of apoptotic cell death resulting from the treatment of lawsone derivative 11a were concentration-dependent, this was not the case for plumbagin (1). Starting from a dosage of 0.5 μM, compound 11a induced higher frequency of HT-29 cells apoptosis, as well as cytotoxic effects at both early and late stages. For plumbagin (1) though, the only discernible effect was seen at a higher threshold (2.5 μM). We attribute this finding to and confirmed that the superior efficiency of lawsone derivative 11a in its cytotoxicity and inhibitive function on human colorectal cell proliferation.

Figure 4.

Figure 4

Open in a new tab

(A) The effects of the 48 h treatments with 0–2.5 μM plumbagin (1) and 11a on apoptotic percentage distribution of HT-29 cells by Annexin V-FITC/PI staining. (B) The apoptosis rate was calculated by flow cytometry and cell apoptosis was defined in early and late apoptosis treatment with 0–2.5 μM plumbagin (1) and 11a for 48 h. Each value represents the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. control.

3. Experimental Section

3.1. General

All chemical reagents of commercial quality were used as received (Sigma-Aldrich, St. Louis, MO, USA) and were used without further purification. Solvents were dried and the synthesized compounds were purified using standard techniques. The progression of reactions was monitored by TLC on aluminum plates coated with silica gel with a fluorescent indicator (Merck, Darmstadt, Germany) unless otherwise stated. Melting points were determined using open capillaries using the Fargo MP-2D apparatus (Prosperous instrument, Chaiyi, Taiwan, ROC) and are reported uncorrected. NMR spectra were recorded using TMS as an internal standard in CDCl3 at 500 MHz for 1H and at 125 MHz for 13C (Bruker Biospin GmbH AVANCE III 500 MHz, Rheinstetten, Germany). The mass spectra were acquired using a Thermo Finnigan model LXQ (Thermo Electron Co., Waltham, MA, USA) ion trap mass spectrometer equipped with ESI source interference and controlled by Xcalibur 2.06 (Thermo Electron Co., Waltham, MA, USA). The mass spectra were acquired in a positive ion mode or a negative ion mode. ESI high-resolution mass spectra (HRMS) were recorded on a Finnigan MAT 95S mass spectrometry (Thermo Fisher Scientific Co. Ltd., Waltham, MA, USA). Column chromatography was performed with silica gel SiliaFlash® G60 (60–200 μm, Quebec City, QC, Canada) purchased from SiliCycle Inc. (Quebec City, QC, Canada). In general, the reactions were carried out under anhydrous conditions in dry solvent and nitrogen atmosphere. The purity of the compounds was more than 98% based on the analysis of HPLC (Hitachi High-Technologies, Tokyo, Japan) using a RP-C18 column (4.6 mm × 250 mm, 5 μm, Merck, Darmstadt, Germany).

3.2. General Synthetic Procedure for 5a,b‒11a,b

A mixture of lawsone (2.87 mmol), NaI (3.16 mmol), triethylamine (3.16 mmol) and alkyl or terpenyl bromide (2.87 mmol) were stirred in DMF (5 mL) at 40 °C for three days. After the reaction was cooled to room temperature, 1 N HCl was added and the solution was poured into a separatory funnel with water, dichloromethane was added and the organic layer was separated from the aqueous layer. The organic layer was collected, dried over anhydrous magnesium sulfate (MgSO4) and concentrated under reduced pressure to remove the solvent, and then was subjected to column chromatography (ethyl acetate/n-hexane = 1/7) to produce yellow solid compounds, which were purified by recrystallization from n-hexane.

2-Hydroxy-3-methyl-1,4-naphthoquinone (5a). The reaction produced 5a in 45.3% as a yellow solid; mp 173.4–174.1 °C (lit. [30] 173–174 °C). 1H-NMR (500 MHz, CDCl3) δH 2.09 (s, 3H, CH3), 7.29 (bs, 1H, 2-OH), 7.66 (dt, J = 1.2, 7.5 Hz, 1H, H-7), 7.73 (dt, J = 1.4, 7.6 Hz, 1H, H-6), 8.06 (dd, J = 1.2, 7.7 Hz, 1H, H-8), 8.10 (dd, J = 0.7, 7.7 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 8.91 (CH3), 120.75 (C-3), 126.36 (C-8), 126.97 (C-5), 129.64 (C-9), 133.13 (C-6), 132.94 (C-10), 134.83 (C-7), 153.13 (C-2) 181.19 (C=O), 185.02 (C=O); LC-MS (ESI−, m/z) calculated for C11H8O3: 188.05, found for 186.98 [M − H]−; HRMS-ESI: m/z calculated for C11H8O3: 188.0473 [M]+, found for 188.0471.

2-Methoxy-1,4-naphthoquinone (5b). The reaction produced 5b in 27.0% as a yellow solid; mp 187.0–187.8 °C (lit. [31] 186–189 °C). 1H-NMR (500 MHz, CDCl3) δH 3.89 (s, 3H, CH3), 6.16 (s, 1H, H-3), 7.70 (dt, J = 1.3, 7.5 Hz, 1H, H-7), 7.74 (dt, J = 1.3, 7.5 Hz, 1H, H-6), 8.07 (dd, J = 1.2, 7.5 Hz, 1H, H-8), 8.11 (dd, J = 1.2, 7.5 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 56.65 (CH3), 110.14 (C-3), 126.43 (C-8), 126.96 (C-5), 131.29 (C-9), 132.28 (C-10), 133.58 (C-6), 134.57 (C-7), 160.67 (C-2), 180.36 (C=O), 185.08 (C=O); LC-MS (ESI+, m/z) calculated for C11H8O3: 188.05, found for 189.09 [M + H]+; HRMS-ESI: m/z calculated for C11H8O3: 188.0473 [M]+, found for 188.0476.

2-Hydroxy-3-butyl-1,4-naphthoquinone (6a). The reaction produced 6a in 36.6% as a yellow solid; mp 97.1–98.0 °C (lit. [32] 93–94 °C). 1H-NMR (500 MHz, CDCl3) δH 0.92 (t, J = 7.5 Hz, 3H, CH3), 1.39 (p, J = 7.5 Hz 2H, H-3′), 1.50 (p, J = 7.5 Hz, 2H, H-2′), 2.58 (t, J = 7.5 Hz, 2H, H-1′), 7.30 (s, 1H, 2-OH), 7.65 (t, J = 7.5 Hz, 1H, H-7), 7.73 (t, J = 7.5 Hz, 1H, H-6), 8.05 (d, J = 7.5 Hz, 1H, H-8), 8.10 (d, J = 7.5 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 14.12 (CH3), 23.09 (C-1′), 29.91 (C-3′), 30.64 (C-2′), 125.04 (C-3), 126.26 (C-8), 126.99 (C-5), 129.67 (C-9), 133.06 (C-6), 133.18 (C-10), 135.04 (C-7), 153.23 (C-2), 181.70 (C=O), 184.96 (C=O); LC-MS (ESI−, m/z) calculated for C14H14O3: 230.09, found for 229.05 [M − H]−; HRMS-ESI: m/z calculated for C14H14O3: 230.0943 [M]+, found for 230.0948.

2-Butyloxy-1,4-naphthoquinone (6b). The reaction produced 6b in 5.5% as a yellow solid; mp 111.5–112.1 °C (lit. [33] 97–98 °C). 1H-NMR (500 MHz, CDCl3) δH 0.99 (t, J = 7.4 Hz, 3H, CH3), 1.53 (p, J = 7.5 Hz 2H, H-3′), 1.88 (p, J = 7.1 Hz, 2H, H-2′), 4.02 (t, J = 6.6 Hz, 2H, H-1′), 6.16 (s, 1H, H-3), 7.70 (dt, J = 1.0, 7.5 Hz, 1H, H-7), 7.74 (dt, J = 1.0, 7.5 Hz, 1H, H-6), 8.07 (d, J = 7.3 Hz, 1H, H-8), 8.11 (d, J = 7.3 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 13.70 (CH3), 19.13 (C-3′), 30.25 (C-2′), 69.39 (C-1′), 110.19 (C-3), 126.11 (C-8), 126.68 (C-5), 131.20 (C-9), 132.04 (C-10), 133.26 (C-6), 134.21 (C-7), 159.93 (C-2), 180.18 (C=O), 185.10 (C=O); LC-MS (ESI−, m/z) calculated for C14H14O3: 230.09, found for 229.52 [M − H]−; HRMS-ESI: m/z calculated for C14H14O3: 230.0943 [M]+, found for 230.0941.

2-Hydroxy-3-octyl-1,4-naphthoquinone (7a). The reaction produced 7a in 36.2% as a yellow solid; mp 91.1–91.6 °C (lit. [34] 88–89 °C). 1H-NMR (500 MHz, CDCl3) δH 0.86 (t, J = 7.5 Hz, 3H, CH3), 1.23–1.36 (m, 8H, H-4′, H-5′, H-6′, H-7′), 1.39 (p, J = 8.0 Hz, 2H, H-3′), 1.51 (p, J = 7.6 Hz, 2H, H-2′), 2.58 (t, J = 7.7 Hz, 2H, H-1′), 7.26 (s, 1H, 2-OH), 7.66 (dt, J = 1.0, 7.6 Hz, 1H, H-7), 7.73 (dt, J = 1.0, 7.6 Hz, 1H, H-6), 8.05 (d, J = 7.5 Hz, 1H, H-8), 8.10 (d, J = 7.6 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 14.32 (CH3), 22.88 (C-1′), 28.53 (C-7′), 29.46 (C-2′), 29.64 (C-3′), 29.92 (C-4′), 30.41 (C-5′), 32.10 (C-6′), 125.09 (C-3), 126.27 (C-8), 127.01 (C-5), 129.69 (C-9), 133.06 (C-6), 133.21 (C-10), 135.04 (C-7), 153.20 (C-2), 181.72 (C=O), 184.94 (C=O); LC-MS (ESI+, m/z) calculated for C18H22O3: 286.16, found for 309.35 [M + Na]+; HRMS-ESI: m/z calculated for C18H22O3: 286.1569 [M]+, found for 286.1568.

2-Octyloxy-1,4-naphthoquinone (7b). The reaction produced 7b in 3.8% as a yellow solid; mp 94.1–95.8 °C. 1H-NMR (500 MHz, CDCl3) δH 0.86 (t, J = 6.9, 3H, CH3), 1.23–1.35 (m, 8H, H-4′, H-5′, H-6′, H-7′), 1.44 (p, J = 7.6 Hz, 2H, H-3′), 1.87 (p, J = 7.2 Hz, 2H, H-2′), 3.98 (t, J = 6.7 Hz, 2H, H-1′), 6.12 (s, 1H, H-3), 7.68 (dt, J = 1.5, 7.5 Hz, 1H, H-7), 7.71 (dt, J = 1.0, 7.5 Hz, 1H, H-6), 8.05 (dd, J = 1.0, 7.0 Hz, 1H, H-8), 8.10 (dd, J = 1.5, 7.5 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 14.08 (CH3), 22.63 (C-7′), 25.85 (C-2′), 28.26 (C-3′), 29.14 (C-4′), 29.20 (C-5′), 31.75 (C-6′), 69.69 (C-1′), 110.19 (C-3), 126.11 (C-8), 126.67 (C-5), 131.20 (C-9), 132.05 (C-10), 133.24 (C-6), 134.20 (C-7), 159.92 (C-2), 180.18 (C=O), 185.09 (C=O); LC-MS (ESI+, m/z) calculated for C18H22O3: 286.16, found for 309.25 [M + Na]+; HRMS-ESI: m/z calculated for C18H22O3: 286.1569 [M]+, found for 286.1564.

2-Hydroxy-3-dodectyl-1,4-naphthoquinone (8a). The reaction produced 8a in 56.3% as a yellow solid; mp 88.4–88.9 °C (lit. [35] 85–87 °C). 1H-NMR (500 MHz, CDCl3) δH 0.86 (t, J = 7.0 Hz, 3H, CH3), 1.23–1.35 (m, 18H, H-3′, H-4′, H-5′, H-6′, H-7′, H-8′, H-9′, H-10′, H-11′), 1.51 (p, J = 7.5 Hz, 2H, H-2′), 2.58 (t, J = 7.7 Hz, 2H, H-1′), 7.26 (s, 1H, 2-OH), 7.61 (dt, J = 0.8, 7.5 Hz, 1H, H-7), 7.73 (dt, J = 0.8, 7.5 Hz, 1H, H-6), 8.00 (d, J = 7.5 Hz, 1H, H-8), 8.05 (d, J = 7.5 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 14.33 (CH3), 22.91 (C-1′), 23.62 (C-11′), 28.53 (C-2′), 29.57 (C-3′), 29.68 (C-4′), 29.80 (C-5′), 29.86 (C-6′), 29.88 (C-7′), 29.92 (C-8′), 30.02 (C-9′), 32.14 (C-10′), 125.09 (C-3), 126.26 (C-8), 127.00 (C-5), 129.69 (C-9), 133.05 (C-6), 133.21 (C-10), 135.04 (C-7), 153.20 (C-2), 181.71 (C=O), 184.93 (C=O); LC-MS (ESI−, m/z) calculated for C22H30O3: 342.22, found for 341.38 [M − H]−; HRMS-ESI: m/z calculated for C22H30O3: 342.2195 [M]+, found for 342.2189.

2-Dodectyloxy-1,4-naphthoquinone (8b). The reaction produced 8b in 6.9% as a yellow solid; mp 96.1–96.7 °C. 1H-NMR (500 MHz, CDCl3) δH 0.86 (t, J = 7.0 Hz, 3H, CH3), 1.24–1.33 (m, 16H, H-4′, H-5′, H-6′, H-7′, H-8′, H-9′, H-10′, H-11′), 1.44 (p, J = 7.5 Hz, 2H, H-3′), 1.87 (p, J = 7.1 Hz, 2H, H-2′), 3.98 (t, J = 6.7 Hz, 2H, H-1′), 6.13 (s, 1H, H-3), 7.68 (t, J = 7.3 Hz, 1H, H-7), 7.72 (t, J = 7.3 Hz, 1H, H-6), 8.05 (d, J = 7.4 Hz, 1H, H-8), 8.10 (d, J = 7.5 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 14.33 (CH3), 22.90 (C-7′), 26.06 (C-2′), 28.48 (C-3′), 29.46 (C-4′), 29.56 (C-5′), 29.69 (C-6′), 29.77 (C-7′), 29.83 (C-8′), 29.84 (C-9′), 32.13 (C-10′), 69.90 (C-1′), 110.40 (C-3), 126.32 (C-8), 126.89 (C-5), 131.42 (C-9), 132.26 (C-10), 133.46 (C-6), 134.42 (C-7), 160.13 (C-2), 180.40 (C=O), 185.31 (C=O); LC-MS (ESI−, m/z) calculated for C22H30O3: 342.22, found for 341.30 [M − H]−; HRMS-ESI: m/z calculated for C22H30O3: 342.2195 [M]+, found for 342.2197.

2-Hydroxy-3-isoprenyl-1,4-naphthoquinone (9a). The reaction produced 9a in 58.2% as a yellow solid; mp 142.5–144.0 °C (lit. [36] 141–143 °C). 1H-NMR (500 MHz, CDCl3) δH 1.66 (s, 3H, CH3), 1.77 (s, 3H, CH3), 3.29 (d, J = 7.4 Hz, 2H, H-1′), 5.17–5.21 (m, 2H, H-2′), 7.27 (s, 1H, 2-OH), 7.66 (dt, J = 1.1, 7.4 Hz, 1H, H-7), 7.73 (dt, J = 1.4, 7.6 Hz, 1H, H-6), 8.05 (dd, J = 1.0, 7.4 Hz, 1H, H-8), 8.10 (dd, J = 1.0, 7.7 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 18.12 (CH3), 22.84 (CH3), 25.98 (C-1′), 119.85 (C-3), 123.68 (C-2′), 126.28 (C-8), 127.01 (C-5), 129.65 (C-9), 133.09 (C-6), 133.14 (C-10), 134.09 (C-3ʹ), 135.08 (C-7), 152.87 (C-2), 181.93 (C=O), 184.79 (C=O); LC-MS (ESI−, m/z) calculated for C15H14O3: 242.09, found for 241.16 [M − H]–; HRMS-ESI: m/z calculated for C15H14O3: 242.0943 [M]+, found for 242.0948.

2-Isoprenyloxy-1,4-naphthoquinone (9b). The reaction produced 9b in 4.8% as a yellow solid; mp 158.0–159.6 °C (lit. [37] 150–151 °C). 1H-NMR (500 MHz, CDCl3) δH 1.74 (s, 3H, CH3), 1.79 (s, 3H, CH3), 4.57 (d, J = 7.8 Hz, 2H, H-1′), 5.46–5.49 (m, 2H, H-2′), 6.14 (s, 1H, H-3), 7.68 (dt, J = 1.5, 7.5 Hz, 1H, H-7), 7.72 (dt, J = 1.5, 7.5 Hz, 1H, H-6), 8.06 (dd, J = 1.5, 7.5 Hz, 1H, H-8), 8.10 (dd, J = 1.5, 7.5 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 18.58 (CH3), 26.05 (CH3), 66.63 (C-1′), 110.73 (C-3), 117.41 (C-2′), 126.33 (C-8), 126.92 (C-5), 131.41 (C-9), 132.26 (C-10), 133.46 (C-6), 134.43 (C-7), 140.73 (C-3′), 159.80 (C-2), 180.51 (C=O), 185.28 (C=O); LC-MS (ESI−, m/z) calculated for C15H14O3: 242.09, found for 241.23 [M − H]−; HRMS-ESI: m/z calculated for C15H14O3: 242.0943 [M]+, found for 242.0941.

2-Hydroxy-3-geranyl-1,4-naphthoquinone (10a). The reaction produced 10a in 50.8% as a yellow solid; mp 112.0–112.5 °C [38]. 1H-NMR (500 MHz, CDCl3) δH 1.59 (s, 3H, CH3), 1.65 (s, 3H, CH3), 1.81 (s, 3H, CH3), 1.98–2.01 (m, 2H, H-5′), 2.06–2.09 (m, 2H, H-6′), 3.34 (d, J = 7.5 Hz, 2H, H-1′), 5.06–5.09 (m, 1H, H-7′), 5.23 (dt, J = 1.0, 7.5 Hz, 1H, H-2′), 7.31 (s, 1H, 2-OH), 7.70 (dt, J = 1.0, 7.5 Hz, 1H, H-7), 7.78 (dt, J = 1.0, 7.5 Hz, 1H, H-6), 8.10 (dd, J = 1.5, 7.5 Hz, 1H, H-8), 8.15 (dd, J = 1.0, 7.5 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 16.47 (CH3), 17.88 (CH3), 22.77 (CH3), 25.87 (C-1′), 26.82 (C-6′), 39.96 (C-5′), 119.67 (C-3), 123.76 (C-2′), 124.41 (C-7′), 126.28 (C-8), 127.00 (C-5), 129.65 (C-8′), 131.61 (C-9), 133.08 (C-6), 133.15 (C-10), 135.08 (C-7), 137.61 (C-3′), 152.88 (C-2), 181.94 (C=O), 184.74 (C=O); LC-MS (ESI−, m/z) calculated for C20H22O3: 310.16, found for 309.12 [M − H]−; HRMS-ESI: m/z calculated for C20H22O3: 310.1569 [M]+, found for 310.1572.

2-Geranyloxy-1,4-naphthoquinone (10b). The reaction produced 10b in 5.2% as a pale yellow liquid. 1H-NMR (500 MHz, CDCl3) δH 1.59 (s, 3H, CH3), 1.65 (s, 3H, CH3), 1.81 (s, 3H, CH3), 1.99–2.02 (m, 2H, H-5′), 2.07–2.10 (m, 2H, H-6′), 4.58 (d, J = 6.6 Hz, 2H, H-1´), 5.06–5.10 (m, 1H, H-7´), 5.46 (dt, J = 0.8, 6.6 Hz, 1H, H-2′), 6.14 (s, 1H, H-3), 7.68 (dt, J = 1.0, 7.5 Hz, 1H, H-7), 7.74 (dt, J = 1.0, 7.5 Hz, 1H, H-6), 8.06 (dd, J = 1.5, 7.5 Hz, 1H, H-8), 8.10 (dt, J = 1.0, 7.5 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 16.47 (CH3), 17.68 (CH3), 25.70 (CH3), 26.71 (C-6′), 39.65 (C-5′), 66.51 (C-1′), 110.56 (C-3), 117.22 (C-2′), 124.37 (C-7′), 126.23 (C-8), 126.88 (C-5), 131.18 (C-8′), 132.06 (C-9), 133.18 (C-6), 134.26 (C-10), 135.73 (C-7), 141.56 (C-3′), 159.56 (C-2), 180.29 (C=O), 185.06 (C=O); LC-MS (ESI−, m/z) calculated for C20H22O3: 310.16, found for 309.06 [M − H]−; HRMS-ESI: m/z calculated for C20H22O3: 310.1569 [M]+, found for 310.1574.

2-Hydroxy-3-farnesyl-1,4-naphthoquinone (11a). The reaction produced 11a in 35.2% as a yellow solid; mp 84.4–84.9 °C (lit. [39] 68–69 °C). 1H-NMR (500 MHz, CDCl3) δH 1.54 (s, 3H, CH3), 1.54 (s, 6H, CH3), 1.77 (s, 3H, CH3), 1.92–1.95 (m, 2H, H-5′), 1.97–2.00 (m, 4H, H-9′, H-10′) 2.02–2.07 (m, 2H, H-6′), 3.30 (d, J = 7.5 Hz, 2H, H-1′), 5.00–5.05 (m, 2H, H-7′, H-12′) 5.20 (t, 1H, J = 7.3 Hz, 1H, H-2′), 7.28 (s, 1H, 2-OH), 7.65 (t, J = 7.5 Hz, 1H, H-7), 7.73 (t, J = 7.5 Hz, 1H, H-6), 8.05 (d, J = 7.5 Hz, 1H, H-8), 8.11 (d, J = 7.5 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 16.22 (CH3), 16.48 (CH3), 17.86 (CH3), 22.77 (C-1′), 25.90 (CH3), 26.69 (C-6′), 26.94 (C-11′), 39.89 (C-5′), 39.95 (C-9′), 119.69 (C-3), 123.75 (C-2′), 124.24 (C-7′), 124.57 (C-11′), 126.27 (C-8), 127.00 (C-5), 129.66 (C-9), 131.43 (C-10), 133.06 (C-6), 133.14 (C-12′), 135.06 (C-7), 135.24 (C-8′), 137.60 (C-3′), 152.89 (C-2), 181.92 (C=O), 184.74 (C=O); LC-MS (ESI−, m/z) calculated for C25H30O3: 378.22, found for 377.23 [M − H]−; HRMS-ESI: m/z calculated for C25H30O3: 378.2195 [M]+, found for 378.2193.

2-Farnesyloxy-1,4-naphthoquinone (11b). The reaction produced 11b in 7.4% as a yellow liquid. 1H-NMR (500 MHz, CDCl3) δH 1.56 (s, 3H, CH3), 1.58 (s, 6H, CH3), 1.74 (s, 3H, CH3), 1.92–1.95 (m, 2H, H-5′), 2.00–2.03 (m, 2H, H-6′) 2.08–2.12 (m, 4H, H-9′, H-10′), 4.60 (d, J = 6.6 Hz, 2H, H-1′), 5.04–5.08 (m, 2H, H-7′, H-12′) 5.47 (dt, 1H, J = 0.8, 6.6 Hz, 1H, H-2′), 6.14 (s, 1H, H-3), 7.69 (dt, J = 1.5, 7.5 Hz, 1H, H-7), 7.72 (dt, J = 1.5, 7.5 Hz, 1H, H-6), 8.06 (dd, J = 1.5, 7.5 Hz, 1H, H-8), 8.10 (dd, J = 1.5, 7.5 Hz, 1H, H-5); 13C-NMR (125 MHz, CDCl3) δC 16.05 (CH3), 16.88 (CH3), 17.68 (CH3), 25.70 (CH3), 26.09 (C-6′), 26.71 (C-11′), 39.53 (C-5′), 39.67 (C-9′), 66.50 (C-1′), 110.55 (C-3), 116.91 (C-2′), 123.39 (C-7′), 124.28 (C-11′), 126.12 (C-8), 126.70 (C-5), 131.20 (C-9), 131.33 (C-10), 132.04 (C-12′), 133.24 (C-6), 134.21 (C-7), 135.72 (C-8′), 143.63 (C-3′), 159.58 (C-2), 180.31 (C=O), 185.04 (C=O); LC-MS (ESI−, m/z) calculated for C25H30O3: 378.22, found for 377.26 [M − H]−; HRMS-ESI: m/z calculated for C25H30O3: 378.2195 [M]+, found for 378.2190.

3.3. 5-Hydroxy-1,4-Naphthoquinone (Juglone, 3)

A suspension of 1,5-dihydroxynaphthene (1 g, 6.25 mmol) in THF/H2O (50 mL, 1/1, v/v) was placed in a 100 mL, three-necked flask fitted with a mechanical stirrer and a gas inlet tube and a strong current of air was bubbled through it. Then, periodic acid (3.12 g, 13.7 mmol) was added with vigorous stirring at room temperature in the dark over 1 h, and the resultant mixture was stirred for 4 h. The mixture was filtered, washed with acetonitrile, and the solvent removed under reduced pressure. The crude product was purified using silica gel with ethyl acetate/n-hexane (1:5) as the solvent to afford 5-hydroxy-1,4-naphthoquinone (juglone, 3) (735 mg, 4.22 mmol, 67.6%) as a brown-red solid; mp 146.0–148.2 °C (lit. [40] 152 °C). 1H-NMR (500 MHz, CDCl3) δH 6.93 (s, 2H, H-2, H-3), 7.26 (dd, J = 1.5, 7.5 Hz, 1H, H-6), 7.59–7.63 (m, 2H, H-7, H-8), 11.88 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 114.97 (C-10), 119.15 (C-6), 124.49 (C-8), 131.76 (C-9), 136.56 (C-7), 138.65 (C-3), 139.59 (C-2), 161.45 (C-5), 184.25 (C=O), 190.28 (C=O); LC-MS (ESI−, m/z) calculated for C10H6O3: 174.03, found for 173.10 [M − H]−; HRMS-ESI: m/z calculated for C10H6O3: 174.0317 [M]+, found for 174.0313.

3.4. General Proceed Amination of Juglone with Alkyl Amine

A suspension of juglone (200 mg, 1.15 mmol) and alkyl amine (1.15 mmole) in 50 mL of ethanol was stirred for 1 h under reflux. The mixture was poured into water, 2 mL of 1 N hydrochloric acid was added, the precipitate was filtered off, washed with water, dried, and dissolved in chloroform, and the solution was applied to a column charged with silica gel. The column was eluted with ethyl acetate/n-hexane (1/5) to give the 2-amination and 3-amination products, respectively.

2-Butylamino-5-hydroxy-1,4-naphthoquinone (13a). The reaction produced 13a in 13.9% as an orange red solid; mp 154.6–155.4 °C (lit. [41] 156–157 °C). 1H-NMR (500 MHz, CDCl3) δH 0.96 (t, J = 7.4 Hz, 3H, CH3), 1.43 (p, J = 7.5 Hz, 2H, H-2′), 1.67 (p, J = 7.5 Hz, 2H, H-3′), 3.17 (q, J = 6.9 Hz, 2H, H-1′), 5.61 (s, 1H, H-3), 6.04 (s, 1H, -NH), 7.22 (dd, J = 0.8, 8.3 Hz, 1H, H-8), 7.44 (t, J = 8.0 Hz, 1H, H-7), 7.56 (dd, 1H, J = 0.8, 7.6 Hz, H-6), 13.08 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 13.90 (CH3), 20.40 (C-2′), 30.43 (C-3′), 42.63 (C-1′), 99.81 (C-3), 115.19 (C-9), 119.25 (C-6), 126.18 (C-8), 130.70 (C-10), 134.05 (C-7), 148.90 (C-2), 161.33 (C-5), 181.41 (C=O), 189.14 (C=O); LC-MS (ESI+, m/z) calculated for C14H15NO3: 245.11, found for 268.24 [M + Na]+; HRMS-ESI: m/z calculated for C14H16O3N: 246.1125 [M + H]+, found for 246.1120.

3-Butylamino-5-hydroxy-1,4-naphthoquinone (13b). The reaction produced 13b in 6.9% as an orange red solid; mp 125.3–126.5 °C (lit. [41] 111–112 °C). 1H-NMR (500 MHz, CDCl3) δH 0.96 (t, J = 7.5 Hz, 3H, CH3), 1.42 (h, J = 7.5 Hz, 2H, H-3′), 1.67 (p, J = 7.5 Hz, 2H, H-2′), 3.17 (q, J = 6.9 Hz, 2H, H-1′), 5.70 (s, 1H, H-3), 5.85 (bs, 1H, -NH), 7.12 (dd, J = 2.3, 7.0 Hz, 1H, H-8), 7.57–7.62 (m, 2H, H-6, H-7), 11.52 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 13.91 (CH3), 20.42 (C-2′), 30.45 (C-3′), 42.56 (C-1′), 101.50 (C-3), 114.31 (C-9), 118.95 (C-6), 122.37 (C-8), 133.82 (C-10), 137.91 (C-7), 147.97 (C-2), 161.89 (C-5), 182.42 (C=O), 186.36 (C=O); LC-MS (ESI+, m/z) calculated for C14H15NO3: 245.11, found for 268.29 [M + Na]+; HRMS-ESI: m/z calculated for C14H16O3N: 246.1125 [M + H]+, found for 246.1121.

2-Hexylamino-5-hydroxy-1,4-naphthoquinone (14a). The reaction produced 14a in 15.1% as an orange red solid; mp 126.0–127.5 °C. 1H-NMR (500 MHz, CDCl3) δH 0.88 (t, J = 7.5 Hz, 3H, CH3), 1.30–1.32 (m, 4H, H-4′, H-5′), 1.36–1.40 (m, 2H, H-3′), 1.67 (p, J = 7.3 Hz, 2H, H-2′), 3.16 (q, J = 6.8 Hz, 2H, H-1′), 5.60 (s, 1H, H-3), 6.05 (bs, 1H, -NH), 7.22 (d, J = 8.4 Hz, 1H, H-8), 7.44 (t, J = 7.9 Hz, 1H, H-7), 7.56 (d, J = 7.2 Hz, 1H, H-6), 13.08 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 14.19 (CH3), 22.72 (C-5′), 26.88 (C-2′), 28.38 (C-3′), 31.59 (C-4′), 42.93 (C-1′), 99.78 (C-3), 115.18 (C-9), 119.24 (C-6), 126.16 (C-8), 130.68 (C-10), 134.03 (C-7), 148.87 (C-2), 161.31 (C-5), 181.40 (C=O), 189.12 (C=O); LC-MS (ESI+, m/z) calculated for C16H19NO3: 273.14, found for 296.29 [M + Na]+; HRMS-ESI: m/z calculated for C16H20O3N: 274.1438 [M+H]+, found for 274.1435

3-Hexylaminp-5-hydroxy-1,4-naphthoquinone (14b). The reaction produced 14b in 24.1% as an orange red solid; mp 110.2–111.1 °C. 1H-NMR (500 MHz, CDCl3) δH 0.88 (t, J = 6.4 Hz, 3H, CH3), 1.31–1.32 (m, 4H, H-4′, H-5′), 1.39 (p, J = 6.9 Hz, 2H, H-3′), 1.69 (p, J = 7.3 Hz, 2H, H-2′), 3.16 (q, J = 6.6 Hz, 2H, H-1′), 5.69 (s, 1H, H-2), 5.87 (bs, 1H, -NH), 7.11 (dd, J = 2.0, 7.2 Hz, 1H, H-6), 7.57–7.61 (m, 2H, H-7, H-8), 11.52 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 13.97 (CH3), 22.50 (C-5′), 26.68 (C-2′), 28.17 (C-3′), 31.38 (C-4′), 42.63 (C-1′), 101.24 (C-2), 114.07 (C-9), 118.71 (C-6), 122.14 (C-8), 133.58 (C-10), 137.67 (C-7), 147.73 (C-3), 161.66 (C-5), 182.18 (C=O), 186.11 (C=O); LC-MS (ESI+, m/z) calculated for C16H19NO3: 273.14, found for 296.26 [M + Na]+; HRMS-ESI: m/z calculated for C16H20O3N: 274.1438 [M + H]+, found for 274.1433.

2-Octylamino-5-hydroxy-1,4-naphthoquinone (15a). The reaction produced 15a in 14.1% as an orange red solid; mp 128.2–129.5 °C. 1H-NMR (500 MHz, CDCl3) δH 0.87 (t, J = 6.6 Hz, 3H, CH3), 1.26–1.29 (m, 6H, H-5′, H-6′, H-7′), 1.36–1.39 (m, 4H, H-3′, H-4′), 1.67 (p, J = 7.3 Hz, 2H, H-2′), 3.16 (q, J = 6.6 Hz, 2H, H-1′), 5.60 (s, 1H, H-3), 6.04 (bs, 1H, -NH), 7.22 (d, J = 8.0 Hz, 1H, H-8), 7.44 (t, J = 7.9 Hz, 1H, H-7), 7.57 (d, J = 7.5 Hz, 1H, H-6), 13.08 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 14.29 (CH3), 22.83 (C-7′), 27.22 (C-2′), 28.43 (C-3′), 29.35 (C-4′), 29.92 (C-5′), 31.95 (C-6′), 42.94 (C-1′), 99.80 (C-3), 115.20 (C-9), 119.25 (C-6), 126.18 (C-8), 130.70 (C-10), 134.04 (C-7), 148.88 (C-2), 161.33 (C-5), 181.42 (C=O), 189.14 (C=O); LC-MS (ESI+, m/z) calculated for C18H23NO3: 301.17, found for 324.34 [M + Na]+; HRMS-ESI: m/z calculated for C18H24O3N: 302.1751 [M + H]+, found for 302.1746.

3-Octylamino-5-hydroxy-1,4-naphthoquinone (15b). The reaction produced 15b in 31.4% as an orange red solid; mp 119.5–120.3 °C. 1H-NMR (500 MHz, CDCl3) δH 0.87 (t, J = 6.3 Hz, 3H, CH3), 1.23–1.29 (m, 6H, H-5′, H-6′, H-7′), 1.37–1.39 (m, 2H, H-4′), 1.65–1.70 (m, 4H, H-2′, H-3′), 3.16 (q, J = 6.4 Hz, 2H, H-1′), 5.70 (s, 1H, H-2), 5.87 (bs, 1H, -NH), 7.11 (d, J = 7.3, 1H, H-8), 7.57–7.61 (m, 2H, H-6, H-7), 11.52 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 14.29 (CH3), 22.84 (C-7′), 27.24 (C-2′), 28.45 (C-3′), 29.36 (C-4′), 29.42 (C-5′), 31.96 (C-6′), 42.90 (C-1′), 101.46 (C-2), 114.31 (C-9), 118.98 (C-6), 122.40 (C-8), 133.81 (C-10), 137.93 (C-7), 148.02 (C-3), 161.93 (C-5), 182.40 (C=O), 186.33 (C=O); LC-MS (ESI+, m/z) calculated for C18H23NO3: 301.17, found for 324.36 [M + Na]+; HRMS-ESI: m/z calculated for C18H24O3N: 302.1751 [M + H]+, found for 302.1749.

2-Decylamino-5-hydroxy-1,4-naphthoquinone (16a). The reaction produced 16a in 19.2% as an orange red solid; mp 124.5–125.7 °C. 1H-NMR (500 MHz, CDCl3) δH 0.86 (t, J = 6.8 Hz, 3H, CH3), 1.23–1.30 (m, 8H, H-6′, H-7′, H-8′, H-9′), 1.35–1.40 (m, 6H, H-3′, H-4′, H-5′), 1.67 (p, J = 7.3 Hz, 2H, H-2′), 3.17 (q, J = 6.7 Hz, 2H, H-1′), 5.61 (s, 1H, H-3), 6.05 (bs, 1H, -NH), 7.22 (dd, J = 2.2, 7.3 Hz, 1H, H-8), 7.44 (dt, 1H, J = 1.0, 7.5 Hz, H-7), 7.56 (dd, 1H, J = 1.0, 7.5 Hz, H-6), 13.08 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 14.09 (CH3), 22.65 (C-9′), 26.98 (C-2′), 28.19 (C-3′), 29.20 (C-4′), 29.25 (C-5′), 29.46 (C-6′), 29.47 (C-7′), 31.85 (C-8′), 42.71 (C-1′), 99.57 (C-3), 114.97 (C-9), 119.02 (C-6), 125.95 (C-8), 130.47 (C-10), 133.82 (C-7), 148.66 (C-2), 161.10 (C-5), 181.20 (C=O), 188.91 (C=O); LC-MS (ESI+, m/z) calculated for C20H29NO3: 329.20, found for 352.47 [M + Na]+; HRMS-ESI: m/z calculated for C20H28O3N: 330.2064 [M + H]+, found for 330.2058.

3-Decylamino-5-hydroxy-1,4-naphthoquinone (16b). The reaction produced 16b in 39.5% as an orange red solid; mp 95.8–96.9 °C. 1H-NMR (500 MHz, CDCl3) δH 0.86 (t, J = 6.8 Hz, 3H, CH3), 1.23–1.31 (m, 10H, H-5′, H-6′, H-7′, H-8′, H-9′), 1.35–1.40 (m, 4H, H-3′, H-4′,), 1.67 (p, J = 7.3 Hz, 2H, H-2′′), 3.16 (q, J = 6.7 Hz, 2H, H-1′), 5.68 (s, 1H, H-2), 5.86 (bs, 1H, -NH), 7.11 (dd, J = 2.2, 7.3 Hz, 1H, H-8), 7.57–7.61 (m, 2H, H-6, H-7), 11.51 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 14.32 (CH3), 22.88 (C-9′), 27.24 (C-2′), 28.44 (C-3′), 29.45 (C-4′), 29.48 (C-5′), 29.70 (C-6′), 29.92 (C-7′), 32.08 (C-8′), 42.89 (C-1′), 101.45 (C-2), 114.30 (C-9), 118.97 (C-6), 122.39 (C-8), 133.80 (C-10), 137.91 (C-7), 148.02 (C-3), 161.92 (C-5), 182.38 (C=O), 186.31 (C=O); LC-MS (ESI+, m/z) calculated for C20H29NO3: 329.20, found for 330.26 [M + H]+; HRMS-ESI: m/z calculated for C20H28O3N: 330.2064 [M + H]+, found for 330.2059.

2-Dodecylamino-5-hydroxy-1,4-naphthoquinone (17a). The reaction produced 17a in 15.5% as an orange red solid; mp 121.8–122.2 °C. 1H-NMR (500 MHz, CDCl3) δH 0.86 (t, J = 6.8 Hz, 3H, CH3), 1.24–1.31 (m, 14H, H-5′, H-6′, H-7′, H-8′, H-9′, H-10′, H-11′), 1.34–1.40 (m, 4H, H-3′, H-4′), 1.67 (p, J = 7.3 Hz, 2H, H-2′), 3.16 (q, J = 6.6 Hz, 2H, H-1′), 5.60 (s, 1H, H-3), 6.05 (bs, 1H, -NH), 7.22 (d, J = 8.4 Hz, 1H, H-8), 7.44 (t, 1H, J = 7.9 Hz, H-7), 7.56 (d, 1H, J = 7.5 Hz, H-6), 13.08 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 14.34 (CH3), 22.90 (C-11′), 27.22 (C-2′), 28.42 (C-3′), 29.44 (C-4′), 29.55 (C-5′), 29.69 (C-6′), 29.75 (C-7′), 29.83 (C-8′), 29.92 (C-9′), 32.12 (C-10′), 42.94 (C-1′), 99.80 (C-3), 115.20 (C-9), 119.25 (C-6), 126.18 (C-8), 130.70 (C-10), 134.04 (C-7), 148.88 (C-2), 161.33 (C-5), 181.42 (C=O), 189.13 (C=O); LC-MS (ESI+, m/z) calculated for C22H31NO3: 357.23, found for 380.44 [M + Na]+; HRMS-ESI: m/z calculated for C22H32O3N: 358.2377 [M + H]+, found for 358.2371.

3-Dodecylamino-5-hydroxy-1,4-naphthoquinone (17b). The reaction produced 17b in 24.6% as an orange red solid; mp 98.0–98.5 °C. 1H-NMR (500 MHz, CDCl3) δH 0.86 (t, J = 6.7 Hz, 3H, CH3), 1.24–1.31 (m, 12H, H-6′, H-7′, H-8′, H-9′, H-10′, H-11′), 1.35–1.39 (m, 4H, H-4′, H-5′), 1.65–1.70 (m, 4H, H-2′, H-3′), 3.15 (t, J = 6.1 Hz, 2H, H-1′), 5.70 (s, 1H, H-2), 5.87 (bs, 1H, -NH), 7.11 (d, J = 7.4 Hz, 1H, H-8), 7.57–7.61 (m, 2H, H-6, H-7), 11.52 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 14.34 (CH3), 22.90 (C-11′), 27.24 (C-2′), 28.44 (C-3′), 29.45 (C-4′), 29.55 (C-5), 29.70 (C-6′), 29.76 (C-7′), 29.83 (C-8′), 29.92 (C-9′), 32.13 (C-10′), 42.87 (C-1′), 101.49 (C-2), 114.32 (C-9), 118.95 (C-6), 122.37 (C-8), 133.83 (C-10), 137.91 (C-7), 147.97 (C-3), 161.90 (C-5), 182.42 (C=O), 186.34 (C=O); LC-MS (ESI+, m/z) calculated for C22H31NO3: 357.23, found for 380.46 [M + Na]+; HRMS-ESI: m/z calculated for C22H32O3N: 358.2377 [M + H]+, found for 358.2374.

2-[(2-Aminoethyl)-morpholine]-5-hydroxy-1,4-naphthoquinone (18a). The reaction produced 18a in 38.9% as a red solid; mp 122.0–122.5 °C. 1H-NMR (500 MHz, CDCl3) δH 2.48 (t, J = 4.2 Hz, 4H, H-2′′, H-6′′), 2.67 (t, J = 6.0 Hz, 2H, H-2′), 3.22 (q, J = 5.7 Hz, 2H, H-1′), 3.72 (t, J = 4.6 Hz, 4H, H-3′′, H-5′′), 5.59 (s, 1H, H-3), 6.66 (bs, 1H, -NH), 7.22 (dd, J = 0.9, 8.4 Hz, 1H, H-8), 7.45 (t, J = 7.9 Hz, 1H, H-7), 7.57 (dd, J = 0.9, 7.2 Hz, 2H, H-6), 13.05 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 38.68 (C-1′), 53.39 (C-2′′, C-6′′), 55.68 (C-2′), 67.10 (C-3′′, C-5′′), 100.12 (C-2), 115.18 (C-9), 119.22 (C-6), 126.13 (C-8), 130.76 (C-10), 134.13 (C-7), 148.89 (C-3), 161.32 (C-5), 181.28 (C=O), 189.17 (C=O); LC-MS (ESI−, m/z) calculated for C16H18N2O4: 302.13, found for 301.08 [M − H]−; HRMS-ESI: m/z calculated for C16H18N2O4: 302.1267 [M]+, found for 302.1264.

3-[(2-Aminoethyl)-morpholine]-5-hydroxy-1,4-naphthoquinone (18b). The reaction produced 18b in 16.8% as a red solid; mp 150.2–151.4 °C. 1H-NMR (500 MHz, CDCl3) δH 2.49 (t, J = 8.5 Hz, 4H, H-2′′, H-6′′), 2.69 (t, J = 6.0 Hz, 2H, H-2′), 3.20 (q, J = 5.5 Hz, 2H, H-1′), 3.74 (t, J = 5.0 Hz, 4H, H-3′′, H-5′′), 5.66 (s, 1H, H-3), 6.49 (bs, 1H, -NH), 7.12 (dd, J = 2.7, 6.8 Hz, 1H, H-8), 7.57–7.61 (m, 2H, H-6, H-7), 11.56 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 38.36 (C-1′), 53.16 (C-2′′, C-6′′), 55.49 (C-2′), 66.65 (C-3′′, C-5′′), 99.97 (C-2), 114.94 (C-9), 119.05 (C-6), 125.92 (C-8), 130.55 (C-10), 133.96 (C-7), 148.65 (C-2), 161.11 (C-5), 181.01 (C=O), 188.97 (C=O); LC-MS (ESI−, m/z) calculated for C16H18N2O4: 302.13, found for 301.16 [M − H]−; HRMS-ESI: m/z calculated for C16H18N2O4: 302.1267 [M]+, found for 302.1261.

2-[(3-Aminopropyl)-morpholine]-5-hydroxy-1,4-naphthoquinone (19a). The reaction produced 19a in 29.2% as a red solid; mp 84.5–85.6 °C. 1H-NMR (500 MHz, CDCl3) δH 1.84 (p, J = 5.9 Hz, 2H, H-2′), 2.49 (bs, 4H, H-2′′, H-6′′), 2.54 (t, J = 5.8 Hz, 2H, H-3′), 3.27 (q, J = 5.7 Hz, 2H, H-1′), 3.84 (t, J = 4.6 Hz, 4H, H-3′′, H-5′′), 5.55 (s, 1H, H-3), 7.20 (dd, J = 0.8, 8.0 Hz, 1H, H-8), 7.43 (t, J = 7.9 Hz, 1H, H-7), 7.56 (dd, J = 0.9, 7.6 Hz, 1H, H-6), 8.08 (bs, 1H, -NH), 13.17 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 23.21 (C-2′), 43.15 (C-1′), 53.83 (C-2′′, C-6′′), 57.91 (C-3′), 66.76 (C-3′′, C-5′′), 99.04 (C-2), 115.12 (C-9), 118.89 (C-6), 125.70 (C-8), 130.69 (C-10), 133.70 (C-7), 149.46 (C-3), 161.06 (C-5), 181.21 (C=O), 188.84 (C=O); LC-MS (ESI−, m/z) calculated for C17H20N2O4: 316.14, found for 315.10 [M − H]−; HRMS-ESI: m/z calculated for C17H20O4N2: 316.1423 [M]+, found for 316.1428.

2-[(3-Aminopropyl)-morpholine]-5-hydroxy-1,4-naphthoquinone (19b). The reaction produced 19b in 30.2% as a red solid; mp 101.6–102.7 °C. 1H-NMR (500 MHz, CDCl3) δH 1.84 (p, J = 6.0 Hz, 2H, H-2′), 2.50 (bs, 4H, H-2′′, H-6′′), 2.55 (t, J = 5.8 Hz, 2H, H-3′), 3.25 (q, J = 5.5 Hz, 2H, H-1′), 3.84 (t, J = 4.6 Hz, 4H, H-3′′, H-5′′), 5.63 (s, 1H, H-3), 7.10 (dd, J = 2.2, 7.3 Hz, 1H, H-8), 7.56–7.60 (m, 2H, H-6, H-7), 7.99 (bs, 1H, -NH), 11.63 (s, 1H, 5-OH); 13C-NMR (125 MHz, CDCl3) δC 23.15 (C-2′), 43.24 (C-1′), 53.83 (C-2′′, C-6′′), 58.05 (C-3′), 66.78 (C-3′′, C-5′′), 100.77 (C-3), 114.22 (C-9), 118.60 (C-6), 122.05 (C-8), 133.76 (C-10), 137.55 (C-7), 148.55 (C-2), 161.69 (C-5), 182.17 (C=O), 186.51 (C=O); LC-MS (ESI−, m/z) calculated for C17H20N2O4: 316.14, found for 315.11 [M − H]−; HRMS-ESI: m/z calculated for C17H20O4N2: 316.1423 [M]+, found for 316.1428.

3.5. Biological Activity

3.5.1. Cell Lines and Cell Culture Conditions

All cells were obtained from the Bioresource Collection and Research Center (Hsinchu, Taiwan). Human colorectal adenocarcinoma cells (HT-29) and human promyelocytic leukemia cells (HL-60) cells were cultured in RPMI 1640 (HyClone, Logan, USA) medium, supplemented with 10% fetal bovine serum (FBS, Gibco, Life Technologies, New York, NY, USA) and antibiotics (100 μg/mL streptomycin and 100 units/mL penicillin, Gibco, Life Technologies). Human colorectal adenocarcinoma cells (SW480), human breast adenocarcinoma cells (MCF-7), human hepatocellular carcinoma cells (HepG2), and normal murine embryonic liver cells (BNL CL.2) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, HyClone, Logan, USA), supplemented with 10% fetal bovine serum (FBS) and antibiotics. Human cancer cells were maintained in humidified atmosphere with 5% CO2 and 95% air at 37 °C in a carbon dioxide incubator (SANYO, CO2 incubator, Osaka, Japan).

3.5.2. Cell Viability Assay

The cytotoxic effect of 34 1,4-naphthoquinone derivatives on five human cancer cell lines was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Bionovas Biotechnology Co., Ltd., Toronto, ON, Canada) as described by Mosmann [26]. The MTT assay depends on the mitochondrial enzyme reduction of tetrazolium dye to detect and determine cell viability. Briefly, the cancer cells or normal cells were plated at 5 × 103–1 × 104 cells into 96-well plates and HL-60 cells were plated at 1 × 105 cells/mL into 12-well plates. After overnight growth, cells were treated with various concentrations of 1,4-naphthoquinone derivatives for 24 h, 48 h and 72 h. At the end of treatment, final concentration of 0.5 mg/mL MTT was added, and the cells were incubated for a further 1.5 h. The absorbance was recorded on an ELISA plate reader (SpectraMax 340PC384, Molecular Devices, Sunnyvale, CA, USA) at 540 nm. Cell viability was determined as the test compound concentration required to inhibit tumor cell proliferation by 50% (IC50) from the dose-response curves. All data are reported as average values from triplicate samples and the experiments were repeated at least three times.

3.5.3. Nuclear Staining with Hoechst 33258

HT-29 cells were plate at 7 × 105 cells per 6-cm dish. After overnight, cells were treated with 0.5–2.5 μM plumbagin (1) and 11a for 48 h. The cells of each dish were stained with 5 mM Hoechst 33258 (Sigma-Aldrich, St. Louis, MO, USA). After the cells were incubated in a dark room for 5 min, the cells were washed with PBS and then were observed using a fluorescent microscope (Zeiss, Axio Observer A1, Göttingen, Germany).

3.5.4. Cell Cycle Distribution Analysis

HT-29 cells were plated at a 1 × 106 cells per 6-cm dish and cultured overnight. Then various concentration of 0.5–2.5 μM plumbagin (1) and 11a were added for 48 h. The cells of each dish were harvested, then washed once with PBS and fixed with methanol at 4 °C. After 18 h, the cells of each dish were harvested, washed once with PBS. The cells were resuspended in 473 μL of PBS containing 40 μg/mL propidium iodide (PI) and 40 μg/mL RNase. Cells were incubated in a dark room for 30 min at room temperature then subjected to cell cycle analysis using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) and analyzed using the ModFit 3.0 software (Verity Software House, Topsham, ME, USA, 2008).

3.5.5. Assessment of Apoptotic Analysis

HT-29 cells were plated at a concentration of 1 × 106 cells per 6-cm dish. After overnight growth, cells were treated with 0.5–2.5 μM plumbagin (1) and 11a for 48 h. The cells of each dish were harvested, then washed once with PBS. The cells were resuspended in 500 μL of PBS containing 4 μg/mL PI and 4 μg/mL Annexin-V-FITC (apoptosis detection kit; R & D Systems, Taipei, Taiwan). Cells were incubated in a dark room for 30 min at room temperature then subjected to cell cycle analysis using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). Annexin V-FITC and PI emission were detected in the FL1 and FL2 channels of the flow cytometer, respectively. Flow cytometer data showed three distinct populations of HT-29 cells. The normal healthy cells, early apoptotic, late apoptotic, and necrosis cells were represented by the Annexin V-negative/PI-negative population, Annexin V-positive/PI-negative, Annexin V-positive/PI-positive, and Annexin V-negative/PI-positive cells, respectively. The data were analyzed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) requipped with ModFit 3.0 software (Verity Software House, Topsham, ME, USA).

3.5.6. Statistical Analysis

The values shown are the mean ± SD of three independent experiments. Data are statistically evaluated by the Student’s test from SigmaPlot 11.0 (Systat Software Inc., San Jose, CA, USA) and shown as significantly different when * p < 0.05, ** p < 0.01 and *** p < 0.001.

4. Conclusions

In summary, we have synthesized a series of 2-position and 3-position lipophilic substituted lawsone and juglone derivatives and shown their enhanced their anti-cancer activity. Among these compounds, a lawsone derivative 11a showed a superior cytotoxicity to all others. Furthermore, 11a has better cytotoxicity against human colorectal adenocarcinoma HT-29 cells, over other cell lines, with an IC50 value of 1.99 ± 0.04 μM for 48 h. Cell cycle distribution and apoptotic analysis by flow cytometry indicated that 11a was arrested cell cycle in S phase and induced apoptosis in HT-29. The Hoechst 33258 staining study showed the nuclear condensation of apoptotic with 11a treatment. Furthermore, compound 11a has markedly induced apoptotic morphological changes and nuclear DNA fragmentation. The mechanism of cell growth inhibition of the compound remains the target of future investigations.

Acknowledgments

Gratitude is extended to Christopher Liu for his valuable editorial revision. This study is supported by grants V101E2-001 and V103E2-002 from the Taipei Veterans General Hospital, Taiwan.

Supplementary Materials

Click here for additional data file. (3.8MB, pdf)

Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/20/07/11994/s1.

Author Contributions

Shao-Hung Wang suggested the research work and discussed the experimental data; Chih-Yu Lo determined and analyzed the LC-MS data of all compounds; Zhong-Heng Gwo and Hong-Jhih Lin finalized the experimental work, interpreted the results, and prepared tables and figures; Lih-Geeng Chen designed the research and discussed the results; Jin-Yi Wu and Cheng-Deng Kuo wrote the paper, edited and revised manuscript. All authors read and approved the final manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Sample Availability: Samples of the compounds 3, 5a,b‒11a,b and 13a,b‒19a,b are available from the authors.

References

  • 1.WHO Report. [(accessed on 25 June 2015)]. Available online: http://www.who.int/mediacentre/factsheets/fs297/en/index.html.
  • 2.Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011;61:69–90. doi: 10.3322/caac.20107. [DOI] [PubMed] [Google Scholar]
  • 3.Prasad K.R., Babu K.S., Rao R.R., Suresh G., Rekha K., Murthy J.M., Rani P.U., Rao J.M. Synthesis and insect antifeedant activity of plumbagin derivatives. Med. Chem. Res. 2012;21:578–583. doi: 10.1007/s00044-011-9559-7. [DOI] [Google Scholar]
  • 4.Cowan M.M. Plant products as antimicrobial agents. Clin. Microbiol. Rev. 1999;12:564–582. doi: 10.1128/cmr.12.4.564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Yang J.T., Li Z.L., Wu J.Y., Lu F.J., Chen C.H. An oxidative stress mechanism of shikonin in human glioma cells. PLoS ONE. 2014;9:e94180. doi: 10.1371/journal.pone.0094180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.McBride T.J., Oleson J.J., Woolf D. The activity of streptonigrin against the Rauscher murine leukemia virus in vivo. Cancer Res. 1966;26:727–732. [PubMed] [Google Scholar]
  • 7.Keyes S.R., Loomis R., di Giovanna M.P., Pritsos C.A., Rockwell S., Sartorelli A.C. Cytotoxicity and DNA crosslinks produced by mitomycin analogs in aerobic and hypoxic EMT6 cells. Cancer Commun. 1991;3:351–356. doi: 10.3727/095535491820873812. [DOI] [PubMed] [Google Scholar]
  • 8.Reich E., Goldberg I.H., Rabinowitz M. Structure-activity correlations of actinomycins and their derivatives. Nature. 1962;196:743–748. doi: 10.1038/196743a0. [DOI] [PubMed] [Google Scholar]
  • 9.Atamanyuk D., Zimenkovsky B., Atamanyuk V., Nektegayev I., Lesyk R. Synthesis and biological activity of new thiopyrano[2,3-d]thiazoles containing a naphthoquinone moiety. Sci. Pharm. 2013;81:423–436. doi: 10.3797/scipharm.1301-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Bhasin D., Etter J.P., Chettiar S.N., Mok M., Li P.K. Antiproliferative activities and SAR studies of substituted anthraquinones and 1,4-naphthoquinones. Bioorg. Med. Chem. Lett. 2013;23:6864–6867. doi: 10.1016/j.bmcl.2013.09.098. [DOI] [PubMed] [Google Scholar]
  • 11.Didry N., Dubrevil L., Pinkas M. Activity of anthraquinonic and naphthoquinonic compounds on oral bacteria. Pharmazie. 1994;49:681–683. [PubMed] [Google Scholar]
  • 12.Likhitwitayawuid K., Kaewamatawong R., Ruangrungsi N., Krungkrai J. Antimalarial naphthaquinones from Nepenthes thorelii. Planta Med. 1998;64:237–241. doi: 10.1055/s-2006-957417. [DOI] [PubMed] [Google Scholar]
  • 13.Mathew N., Paily K.P., Abidha, Vanamali P., Kalyanasundaram M., Balaraman K. Macrofilaricidal activity of the plant Plumbago indica/rosea in vitro. Drug Dev. Res. 2002;56:33–39. doi: 10.1002/ddr.10056. [DOI] [Google Scholar]
  • 14.Kayser O., Kiderlen A.F., Laatsch H., Croft S.L. In vitro leishmanicidal activity of monomeric and dimeric naphthoquinones. Acta Trop. 2000;76:131–138. doi: 10.1016/S0001-706X(00)00078-4. [DOI] [PubMed] [Google Scholar]
  • 15.Nguyen A.T., Malonne H., Duez P., Vanhaelen-Fastre R., Vanhaelen M., Fontaine J. Cytotoxic constituents from Plumbago zeylanica. Fitoterapia. 2004;75:500–504. doi: 10.1016/j.fitote.2004.03.009. [DOI] [PubMed] [Google Scholar]
  • 16.Luo P., Wong Y.F., Ge L., Zhang Z.F., Liu Y., Liu L., Zhou H. Anti-inflammatory and analgesic effect of plumbagin through inhibition of nuclear factor-κB activation. J. Pharmacol. Exp. Ther. 2010;335:735–742. doi: 10.1124/jpet.110.170852. [DOI] [PubMed] [Google Scholar]
  • 17.Thomson R.H. Naturally Occurring Quinones, IV. Recent Advances. Blackie Academic & Professional; London, UK: 1997. [Google Scholar]
  • 18.Eldhose B., Gunawan M., Rahman M., Latha M.S., Notario V. Plumbagin reduces human colon cancer cell survival by inducing cell cycle arrest and mitochondria-mediated apoptosis. Int. J. Oncol. 2014;45:1913–1920. doi: 10.3892/ijo.2014.2592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Subramaniya B.R., Srinivasan G., Sadullah S.S., Davis N., Subhadara L.B., Halagowder D., Sivasitambaram N.D. Apoptosis inducing effect of plumbagin on colonic cancer cells depends on expression of COX-2. PLoS ONE. 2011;6:e18695. doi: 10.1371/journal.pone.0018695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Pertino M.W., Theoduloz C., Palenzuela J.A., Afonso M.M., Yesilada E., Monsalve F., González P., Droguett D., Schmeda-Hirschmann G. Synthesis and pharmacological activity of diterpenylnaphthoquinone derivatives. Molecules. 2011;16:8614–8628. doi: 10.3390/molecules16108614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Del Corral J.M.M., Castro M.A., Gordaliza M., Martín M.L., Gualberto S.A., Gamito A.M., Cuevas C., San Feliciano A. Synthesis and cytotoxicity of new aminoterpenylquinones. Bioorg. Med. Chem. 2005;13:631–644. doi: 10.1016/j.bmc.2004.10.059. [DOI] [PubMed] [Google Scholar]
  • 22.Kawamura M., Kuriyama I., Maruo S., Kuramochi K., Tsubaki K., Yoshida H., Mizushina Y. Anti-tumor effects of novel 5-O-acyl plumbagins based on the inhibition of mammalian DNA replicative polymerase activity. PLoS ONE. 2014;9:e88736. doi: 10.1371/journal.pone.0088736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kuo S.C., Ibuka T., Huang L.J., Lien J.C., Yean S.R., Huang S.C., Lednicer D., Morris-Natschke S., Lee K.H. Synthesis and cytotoxicity of 1,2-disubstituted naphth[2,3-d]imidazole-4,9-diones and related compounds. J. Med. Chem. 1996;39:1447–1451. doi: 10.1021/jm950247k. [DOI] [PubMed] [Google Scholar]
  • 24.Bonifazi E.L., Ríos-Luci C., León L.G., Burton G., Padrón J.M., Misico R.I. Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol. Bioorg. Med. Chem. 2010;18:2621–2630. doi: 10.1016/j.bmc.2010.02.032. [DOI] [PubMed] [Google Scholar]
  • 25.Bhasin D., Chettiar S.N., Etter J.P., Mok M., Li P.K. Anticancer activity and SAR studies of substituted 1,4-naphthoquinones. Bioorg. Med. Chem. 2013;21:4662–4669. doi: 10.1016/j.bmc.2013.05.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65:55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  • 27.Lo C.Y., Hsu L.C., Chen M.S., Lin Y.J., Chen L.G., Kuo C.D., Wu J.Y. Synthesis and anticancer activity of a novel series of 9-O-substituted berberine derivatives: A lipophilic substitute role. Bioorg. Med. Chem. Lett. 2013;23:305–309. doi: 10.1016/j.bmcl.2012.10.098. [DOI] [PubMed] [Google Scholar]
  • 28.Mallavadhani U.V., Prasad C.V., Shrivastava S., Naidu V.G. Synthesis and anticancer activity of some novel 5,6-fused hybrids of juglone based 1,4-naphthoquinones. Eur. J. Med. Chem. 2014;83:84–91. doi: 10.1016/j.ejmech.2014.06.012. [DOI] [PubMed] [Google Scholar]
  • 29.Wu J.Y., Kuo C.D., Chu C.Y., Chen M.S., Lin J.H., Chen Y.J., Liao H.F. Synthesis of novel lipophilic N-substituted norcantharimide derivatives and evaluation of their anticancer activities. Molecules. 2014;19:6911–6928. doi: 10.3390/molecules19066911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hadjila D., Mohamed H. Activated zeolites and heteropolyacids: An efficient catalysts for the synthesis of triacetoxyaromatic precursors of hydroxyquinones. Asian J. Chem. 2013;25:6112–6116. [Google Scholar]
  • 31.Ishiguro K., Ohira Y., Oku H. Antipruritic Dinaphthofuran-7,12-dione Derivatives from the Pericarp of Impatiens balsamina. J. Nat. Prod. 1998;61:1126–1129. doi: 10.1021/np9704718. [DOI] [PubMed] [Google Scholar]
  • 32.Bieber L.W., Rolim Neto P.J., Generino R.M. Regioselective alkylation of substituted quinones by trialkylboranes. Tetrahedron Lett. 1999;40:4473–4476. doi: 10.1016/S0040-4039(99)00804-7. [DOI] [Google Scholar]
  • 33.Lien J.C., Huang L.J., Teng C.M., Wang J.P., Kuo S.C. Synthesis of 2-alkoxy 1,4-naphthoquinone derivatives as antiplatelet, antiinflammatory, and antiallergic agents. Chem. Pharm. Bull. 2002;50:672–674. doi: 10.1248/cpb.50.672. [DOI] [PubMed] [Google Scholar]
  • 34.Fieser L.F. Naphthoquinone Antimalarials. IV-XI. Synthesis. J. Am. Chem. Soc. 1948;70:3174–3215. doi: 10.1021/ja01190a004. [DOI] [PubMed] [Google Scholar]
  • 35.Fugitt R.B., Schwing G.W. Miticidal Ethers. 4,110,473. US Patent. 1978 Aug 29;
  • 36.Kishore N., Mishra B.B., Tiwari V.K., Tripathi V. Difuranonaphthoquinones from Plumbago zeylanica roots. Phytochem. Lett. 2010;3:62–65. doi: 10.1016/j.phytol.2009.11.007. [DOI] [Google Scholar]
  • 37.Inoue K., Ueda S., Nayeshiro H., Moritome N., Inouye H. Biosynthesis of naphthoquinones and anthraquinones in Streptocarpus dunnii cell cultures. Phytochemistry. 1984;23:313–318. doi: 10.1016/S0031-9422(00)80324-6. [DOI] [Google Scholar]
  • 38.Fiorito S., Epifano F., Bruyere C., Mathieu V., Kiss R., Genovese S. Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives. Bioorg. Med. Chem. Lett. 2014;24:454–457. doi: 10.1016/j.bmcl.2013.12.049. [DOI] [PubMed] [Google Scholar]
  • 39.Gebauer M. Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg. Med. Chem. 2007;15:2414–2420. doi: 10.1016/j.bmc.2007.01.014. [DOI] [PubMed] [Google Scholar]
  • 40.Yavorskyy A., Shvydkiv O., Limburg C., Nolan K., Delauré Y.M.C., Oelgemöller M. Photooxygenations in a bubble column reactor. Green Chem. 2012;14:888–892. doi: 10.1039/c2gc16439f. [DOI] [Google Scholar]
  • 41.Bukhtoyarova A.D., Rybalova T.V., Ektova L.V. Amination of 5-hydroxy-1,4-naphthoquinone in the presence of copper acetate. Russ. J. Org. Chem. 2010;46:855–859. doi: 10.1134/S1070428010060126. [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (3.8MB, pdf)

Articles from Molecules are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES